Portal de Periódicos da CAPES

Central actions of β‐adrenoceptor blocking drugs in man

1981; Wiley; Volume: 1; Issue: 4 Linguagem: Inglês

10.1002/med.2610010405

1098-1128

Lata Patel, Paul Turner,

Treatment of Major Depression

Medicinal Research ReviewsVolume 1, Issue 4 p. 387-410 Article Central actions of β-adrenoceptor blocking drugs in man Lata Patel, Lata Patel Department of Clinical Pharmacology, St. Bartholomew's Hospital, London, England EC1A 7BE Lata Patel was born and received her elementary education in Malawi before settling in England where she studied Pharmacology at Chelsea College, University of London, Graduating B.Sc (Honors) in 1979. Since that time she has been investigating factors influencing disposition and metabolism of beta-adrenoceptor blocking drugs in man, particularly their penetration into the brain and cerebrospinal fluid.Search for more papers by this authorPaul Turner, Paul Turner Department of Clinical Pharmacology, St. Bartholomew's Hospital, London, England EC1A 7BE Paul Turner received his medical training at the middlesex Hospital, London, graduating MB in 1958. After 3 years in general medicine at the Middlesex, Royal Free Hospital and Edgware General Hospital, he joined the Department of Pharmacology at St. Bartholomew's Hospital, where he investigated methods for measuring drug effects on CNS function in man. In 1964, he began to develop clinical pharmacology at St. Bartholomew's Hospital, being appointed consultant physician in 1967 and professor of clinical pharmacology in 1972. His main interests have been in clinical autonomic pharmacology and psychopharmacology, and he is the author or co-author of 4 textbooks and co-editor of Recent Advances in Clinical Pharmacology.Search for more papers by this author Lata Patel, Lata Patel Department of Clinical Pharmacology, St. Bartholomew's Hospital, London, England EC1A 7BE Lata Patel was born and received her elementary education in Malawi before settling in England where she studied Pharmacology at Chelsea College, University of London, Graduating B.Sc (Honors) in 1979. Since that time she has been investigating factors influencing disposition and metabolism of beta-adrenoceptor blocking drugs in man, particularly their penetration into the brain and cerebrospinal fluid.Search for more papers by this authorPaul Turner, Paul Turner Department of Clinical Pharmacology, St. Bartholomew's Hospital, London, England EC1A 7BE Paul Turner received his medical training at the middlesex Hospital, London, graduating MB in 1958. After 3 years in general medicine at the Middlesex, Royal Free Hospital and Edgware General Hospital, he joined the Department of Pharmacology at St. Bartholomew's Hospital, where he investigated methods for measuring drug effects on CNS function in man. In 1964, he began to develop clinical pharmacology at St. Bartholomew's Hospital, being appointed consultant physician in 1967 and professor of clinical pharmacology in 1972. His main interests have been in clinical autonomic pharmacology and psychopharmacology, and he is the author or co-author of 4 textbooks and co-editor of Recent Advances in Clinical Pharmacology.Search for more papers by this author First published: Winter 1981 https://doi.org/10.1002/med.2610010405Citations: 42 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 R. P. Ahlquist, Am. J. Physiol., 153, 586– 600 (1948). 2 A. M. Lands, A. Arnold, J. P. Anliff, L. P. Luduena and T. G. Brown, Nature (London), 214, 597 (1967). 3 R. Norrby, J. Antimicrob. Chemother., 5, 630– 632 (1979). 4 W. H. Oldendorf, in The Ocular and Cerebrospinal fluids, L. Z. Bito, H. Davson, J. D. Fenstermacher, Eds., Academic, London, 1978, 177– 190. 5 W. C. Bowman and M. J. Rand, in Textbook of Pharmacology, 2nd ed., Blackwell, Oxford, 1980, Chaps. 6 and 40. 6 M. J. Eadie and J. H. Tyrer, in Neurological Clinical Pharmacology, MTP Press, England, 1980, pp. 1– 24. 7 L. S. Goodman and A. Gilman, in The Pharmacological Basis of Therapeutics, 4th ed., Macmillan, New York, 1970. 8 A. Goldstein, L. Aronow, and S. M. Kalman, in Principles of Drug Action: The Basis of Pharmacology, 2nd ed., Wiley, New York, 1974, pp. 184– 210. 9 S. B. Matin, S. H. Wan, and J. H. Karam, Clin. Pharmacol. Ther., 16, 1052– 1058 (1974). 10 A. Levy, S. H. Ngan, A. D. Fuick, K. Kawashima, and S. Spector, Eur. J. Pharmacol., 40, 93– 100 (1976). 11 R. Laverty and K. M. Taylor, J. Pharm. Pharmacol., 20, 605– 612 (1968). 12 A. Hayes and R. G. Cooper, J. Pharmacol. Exp. Ther., 176, 302– 311 (1971). 13 M. G. Myers, P. J. Lewis, J. L. Reid, and C. T. Dollery, J. Pharmacol. Exp. Ther., 192, 327– 335 (1975). 14 O. M. Bakke, C. T. Dollery, P. J. Lewis, M. G. Myers, and J. L. Reid, Br. J. Pharmacol., 51, 148P (1974). 15 D. J. Tocco, B. V. Clineschmidt, A. E. W. Duncan, F. A. Deluna, and J. E. Baer, J. Cardiovasc. Pharmacol., 2, 133– 143 (1980). 16 G. Leskovszky and L. Tardos, J. Pharm. Pharmacol., 17, 518– 520 (1965). 17 H. L. Garvey, N. Ram, B. Woodhouse, and W. M. Booker, Fed. Proc., 31, 382 (1972). 18 H. L. Garvey and N. Ram, J. Pharmacol. Exp. Ther., 194, 220– 233 (1975). 19 I. B. Linden, P. Ylitalo, A. Pentilla, and H. Vapaatalo, 7th International Congress on Pharmacology, Paris, Abstract No. 721, 615-7 PH, July (1978). 20 M. D. Day, B. A. Hemsworth, and J. A. Street, J. Pharm. Pharmacol., 29, 52P (1977). 21 J. A. Street, B. A. Hemsworth, A. G. Roach, and M. D. Day, Arch. Intern. Pharmacodyn. Ther., 237, 180– 190 (1979). 22 L. E. Martin, R. Hopkins, and R. Bland, Br. J. Clin. Pharmacol., 3(Suppl. 3), 695– 710 (1976). 23 E. A. Taylor, D. Carroll, and P. Turner, Br. J. Clin. Pharmacol., 7, 447P (1978). 24 E. A. Taylor, D. Carroll, and D. Jefferson, Br. J. Clin. Pharmacol., 8, 381– 382P (1979). 25 H. Davson, J. Physiol., 255, 1– 28 (1976). 26 G. Neil-Dwyer, J. Bartlett, J. McAinsh, and J. M. Cruickshank, Br. J. Clin. Pharmacol., to appear. 27 H. Sundquist, Curr. Ther. Res. Clin. Exp., 28, 38S– 44S (1980). 28 S. Kakuichi and T. W. Rall, Mol. Pharmacol., 4, 367– 368 (1968). 29 D. B. Bylund and S. H. Snyder, Mol. Pharmacol., 12, 568– 580 (1976). 30 M. E. Maguire, R. A. Wiklund, H. J. Anderson, and A. G. Gilman, J. Biol. Chem., 251, 1221– 1231 (1976). 31 A. G. Gilman and B. K. Schner, Mol. Pharmacol., 8, 410– 416 (1972). 32 D. Atlas, V. I. Teichberg, and J. P. Changeux, Brain Res., 128, 532– 536 (1977). 33 E. R. Siggins, B. J. Hoffer, and F. E. Bloom, Brain Res., 25, 535– 544 (1971). 34 J. Conway, D. T. Greenwood, and D. N. Middlemiss, Clin. Sci. Mol. Med., 54, 119– 124 (1978). 35 A. Tartara, P. Bo, F. Savoldi, and L. Bolzani, Farmaco (PaviaI 32, 576– 579 (1977). 36 M. Weinstock, C. Weiss, and S. Gitter, Neuropharmacology, 16, 273– 276 (1977). 37 D. N. Middlemiss, L. Blakeborough, and S. R. Leather, Nature, 267, 289– 290 (1977). 38 A. R. Green and D. G. Grahame-Smith, Nature, 262, 594– 596 (1976). 39 A. N. Nicholson and C. M. Wright, Br. J. Pharmacol., 68, 75– 82 (1980). 40 R. W. Alexander, J. N. Davis, and R. J. Lefkowitz, Nature (London), 258, 437– 440 (1975). 41 A. Dolphin, J. Adrien, M. Hamon, and J. Bockaert, Mol. Pharmacol., 15, 1– 15 (1978). 42 S. I. Harik, V. K. Sharma, J. R. Wetherbee, R. H. Warren, and S. P. Banerjee, Eur. J. Pharmacol., 61, 207– 208 (1980). 43 R. J. Lefkowitz, Ann. Intern. Med., 91, 450– 458 (1979). 44 C. P. Mustchin, H. R. Gribbin, A. E. Tattersfield, and C. F. George, Br. Med. J., 2, 1229– 1231 (1976). 45 J. M. Patrick, J. Tutty, and S. B. Pearson, Clin. Sci. Mol. Med., 55, 491– 497 (1978). 46 H. Folgering and J. Braakhekke, Respiration, 39, 139– 143 (1980). 47 P. W. Trembath, E. A. Taylor, J. Varley, and P. Turner, Clin. Sci., 57, 465– 468 (1979). 48 E. Bosisio, M. Sergi, R. Sega, and A. Libretti, Respiration, 37, 197– 200 (1979). 49 J. M. Patrick and S. B. Pearson, Br. J. Clin. Pharmacol., 10, 624– 625 (1980). 50 P. Turner, Br. J. Clin. Pharmacol. 10, 93– 99 (1980). 51 G. Simon, W. Kiowski, and S. Julius, Clin. Pharmacol. Ther., 22, 293– 298 (1977). 52 R. D. S. Watson, T. J. Stallard, and W. A. Littler, Clin. Sci., 57, 241– 247 (1979). 53 D. A. Davies and J. L. Reid, in Central Action of Drugs in Blood Pressure Regulation, Pitman, Tunbridge Wells, 1976. 54 E. C. Johnstone and I. N. Ferrier, Br. J. Clin. Pharmacol., 10, 5– 21 (1980). 55 J. Roubicek, M. Matejcek, and R. Porsolt, Int. J. Neurol., 10, 33– 40 (1975). 56 W. Bender, W. Greil, E. Ruther, and K. Schnelle, J. Clin. Pharmacol., 19, 505– 512 (1979). 57 J. W. Jefferson, Arch. Gen. Psychiatry, 31, 681– 690 (1974). 58 T. O. Morgan, W. J. Louis, J. K. Dawborn, and A. E. Doyle, Med. J. Aust., 2, 309– 312 (1972). 59 J. J. McNeil and W. J. Louis, Br. J. Clin. Pharmacol., 8, 163S– 166S (1979). 60 K. Kayed and O. B. Godttibsen, Eur. J. Clin. Pharmacol., 12, 323– 327 (1977). 61 R. Fleminger, Br. Med. J., 1, 1182 (1978). 62 F. A. Whittock and A. R. Bonfield, Med. J. Aust., 1, 184– 185 (1980). 63 H. J. Waal-Manning, Br. Med. J., 2, 50 (1967). 64 L. Helson and L. Duque, Lancet, 1, 98 (1978). 65 B. M. Kuhr, J. Clin. Psychiatry, 40, 74– 75 (1979). 66 R. H. Robson, Br. Heart J., 39, 1157 (1977). 67 J. P. Crawford, Br. Med. J., 2, 1156– 1157 (1977). 68 P. C. Bryan, D. O. Efiong, J. Stewart-Jones, and P. Turner, Br. J. Clin. Pharmacol., 1, 82– 84 (1974). 69 A. D. Broadhurst, Curr. Med. Res. Opin., 7, 33– 37 (1980). 70 A. A. Landauer, L. B. Jellett, and J. Kirk, Pharmacol. Biochem. Behav., 4, 283– 287 (1976). 71 A. A. Landauer, D. A. Pocock, and F. W. Prott, Psychopharmacology, 60, 211– 215 (1979). 72 D. H. Glaister, M. H. Harrison, and M. F. Allnutt, Environmental influences on cardiac activity, in New Perspectives in β-Blockade, D. M. Burley, J. H. Frier, R. K. Rondel, and S. H. Taylor, Eds., Ciba, Horsham, 1973. 73 N. Farhoumand, J. Harrison, C. M. B. Pare, P. Turner, and S. Wynn, Psychopharmacology, 64, 365– 369 (1979). 74 C. W. Ogle, P. Turner, and H. Markomihelakis, Psychopharmacologia, 46, 295– 299 (1976). 75 W. C. Bowman and E. Zaimis, J. Physiol. (London), 144, 92– 107 (1958). 76 E. Zaimis, Lancet, 1, 403– 405 (1973). 77 C. D. Marsden, T. H. Foley, D. A. L. Owen, and R. G. McAllister, Clin. Sci., 33, 53– 65 (1967). 78 D. Harms and D. Nechvatal, "Decrease of visual reaction time during β-blocker medication," Abstracts of 8th European Congress of Cardiology (1980). 79 P. Turner, K. L. Granville-Grossman, and J. V. Smart, Lancet, 2, 1316– 1318 (1965). 80 P. Turner, Proc. R. Soc. Med., 69, 375– 377 (1976). 81 K. L. Granville-Grossman and P. Turner, Lancet, 1, 788– 790 (1966). 82 D. Wheatley, Br. J. Psychiatry, 115, 1411– 1412 (1969). 83 M. M. Suzman, Postgrad. Med. J., 47, (Suppl.), 104– 108 (1971). 84 P. J. Tyrer and M. H. Lader, Br. Med. J., 2, 14– 16 (1974). 85 J. A. Bonn and P. Turner, Lancet, 1, 1355– 1356 (1971). 86 J. A. Bonn, P. Turner, and D. C. Hicks, Lancet, 1, 814– 815 (1972). 87 J. D. Easton and D. G. Sherman, Arch. Neurol., 33, 689– 691 (1976). 88 J. F. Heiser and D. Defranasio, Am. J. Psychiatry, 133, 1389– 1394 (1976). 89 F. A. Whitlock and J. Price, Curr. Ther., 15, 107– 122 (1974). 90 G. D. Burrows, B. Davies, L. Fail, C. Poynton, and H. Stevenson, Psychopharmacology, 50, 177– 179 (1976). 91 J. O. Cole, South. Med. J., 71(Suppl. 2), 10– 14 (1978). 92 W. Somerville, P. Taggart, and M. Carruthers, Cardiovascular responses in public speaking and their modification by oxprenolol, in New Perspectives in Beta-Blockade, D. M. Burley, J. H. Frier, R. K. Randel, and S. H. Taylor, Eds., Ciba, Horsham, 1973. 93 P. Taggart and M. Carruthers, Behaviour patterns and emotional stress in the etiology of coronary heart disease, in Stress and the Heart, D. Wheatly, Ed., Raven, New York, 1977. 94 I. M. James, R. M. Pearson, D. N. W. Griffith, and P. Newbury, Lancet, 2, 952– 954 (1977). 95 L. C. Antal and C. S. Good, R. Soc. Med. Inter. Congr. Symp., 14, 79– 81 (1979). 96 L. Moser, R. G. Dellen, and P. V. Lundt, Med. Klin. (Munich), 74, 1500– 1504 (1979). 97 M. Ebadi, Gen. Pharmacol., 11, 257– 260 (1980). 98 D. Jefferson, P. Jenner, and C. D. Marsden, J. Neurol. Neurosurg. Psychiatry, 42, 904– 909 (1979). 99 O. Ljung, N. Engl. J. Med., 301, 1005 (1979). 100 O. Ljung, Lancet, 1, 1032 (1980). 101 G. W. Fowler, Neuropadiatrie, 7, 443– 449 (1976). 102 N. M. Bacher and H. A. Lewis, Am. J. Psychiatry, 137, 495– 497 (1980). 103 F. A. Kulik and R. Wilbur, Psychopharmac. Bull., 16, 18– 19 (1980). 104 S. C. Risch, R. M. Cohen, and N. H. Kalin, Am. J. Psychiatry, 137, 1125 (1980). 105 R. Rabkin, D. P. Stables, N. W. Levin, and M. M. Suzman, Am. J. Cardiol., 18, 370– 383 (1966). 106 M. Bekes, L. Matos, J. Rausch, and E. Torok, Lancet, 2, 980 (1968). 107 P. Wykes, Practitioner, 200, 702– 704 (1968). 108 S. Diamond and J. L. Medina, Headache, 16, 24– 27 (1976). 109 B. Forssman, K. G. Henriksson, V. Johannsson, L. Lindwall, and H. Lundin, Headache, 16, 238– 245 (1976). 110 P. Stensrud and O. Sjaastad, Headache, 20, 204– 207 (1980). 111 R. S. Briggs and P. A. Millac, Headache, 19, 379– 381 (1979). 112 O. Sjaastad and P. Stensrud, Acta Neurol. Scand., 48, 124– 128 (1972). 113 K. Ekbom, Headache, 15, 129– 132 (1975). 114 R. N. Nanda, R. H. Johnson, J. Gray, H. J. Keogh, and I. D. Melville, Headache, 18, 20– 22 (1978). 115 E. S. Johnson, Postgrad. Med. J., 54, 231– 242 (1978). 116 A. I. Atsmon and J. Blum, Lancet, I, 196– 197 (1970). 117 D. Douer, A. Weinberger, J. Pinkhas, and A. Atsmon, J. Am. Med. Assoc., 240, 766– 768 (1978). 118 N. J. Yorkston, S. A. Zaki, M. K. V. Malik, R. C. Morrison, and C. W. H. Harand, Br. Med. J., 4, 633– 635 (1974). 119 A. Atsmon, J. Blum, H. Wijsenbeek, B. Maoz, M. Steiner, and G. Ziegelman, Psychiatr. Neurolog. Neurochir., 74, 251– 258 (1971). 120 G. Gardos, J. O. Cole, M. H. Orzack, and L. Volicer, Psychopharmacol. Bull., 9, 43– 44 (1973). 121 W. Rackensperger, R. Gaupp, D. J. Mattke, D. Schwarz, and K. H. Stutte, Arch. Psychiat. Nervenkr., 219, 29– 36 (1974). 122 N. J. Yorkston, J. H. Gruzelier, S. A. Zaki, D. Hollander, D. R. Pitcher, and H. G. S. Sergeant, Lancet, 2, 575– 578 (1977). 123 T. Hanssen, T. Heyden, I. Sundberg, G. Alfredsson, H. Nyback, and L. Wetterberg, Arch. Gen. Psychiatry, 37, 685– 690 (1980). 124 G. P. Sheppard, Br. J. Psychiatry, 134, 470– 476 (1979). 125 L. H. Lindstrom and E. Persson, Br. J. Psychiatry, 137, 126– 130 (1980). 126 M. H. Orzack, R. Branconnier, and G. Gardos, Psychopharmacology, 29, 299– 306 (1973). 127 J. Gruzelier, S. Thornton, D. Staniforth, S. Zaki, and N. Yorkston, Br. J. Psychiatry, 137, 131– 137 (1980). 128 R. H. Belmaker, R. P. Ebstein, H. Dasberg, A. Levy, G. Sedvall, and H. M. Van Praag, Psychopharmacology, 63, 293– 296 (1979). 129 R. H. Belmaker, R. P. Ebstein, J. Biederman, R. Stern, M. Berman, and H. M. Van Praag, Psychopharmacology, 58, 307– 310 (1978). 130 M. Peet, D. N. Middlemiss, and R. A. Yates, Lancet, 2, 978 (1980). 131 P. Turner, Correlation between plasma levels and pharmacological effects, in Topics in Therapeutics, R. G. Shanks, Ed., Pitman, Tunbridge Wells, 1977, Vol. 3. 132 H. M. Emrich, D. V. Zerssen, H. J. Moller, W. Kissling, C. Cording, H. J. Schietsch, and E. Riedel, Pharmakopsychiatr. Neuro-Psychopharmakol., 12, 295– 304 (1979). 133 W. Rackensperger, W. Fritsch, D. Schwarz, K. H. Stutte, and D. V. Zerssen, Arch. Psychiat. Nervenkr., 222, 223– 243 (1976). 134 I. Munro, Editorial, Lancet, 2, 627– 628 (1980). 135 C. Carlsson and T. Johansson, Br. J. Psychiatry, 119, 605– 606 (1971). 136 E. P. Noble, E. Parker, R. Alkana, H. Cohen, and H. Birch, Fed. Proc., 32, 724 (1973). 137 R. L. Alkana, E. S. Parker, H. B. Cohen, H. Birch, and E. P. Noble, Psychopharmacology, 51, 29– 37 (1976). 138 H. J. Grosz, J. Indiana State Med. Assoc., 505– 509 (1972). 139 R. B. Resnick, R. S. Kesterbaum, L. K. Schwartz, and A. Smith, Arch. Gen. Psychiatry, 33, 993– 997 (1976). 140 H. Lowenstein, Lancet, 1, 559– 560 (1973). 141 A. Linken, Lancet, 2, 1039– 1040 (1971). 142 A. Sulkowski, L. Vachon, and E. S. Rich, Psychopharmacology, 52, 47– 53 (1977). 143 M. J. B. Farebrother, S. J. Pearce, P. Turner, and D. R. Appleton, Br. J. Dis. Chest, 74, 95– 96 (1980). 144 S. A. Shevitz, R. C. Jameison, W. M. Petrie, and J. E. Crook, J. Nerv. Ment. Dis., 168, 246– 248 (1980). 145 F. A. Elliot, Ann. Neurol., 1, 489– 491 (1977). 146 M. H. Lader and P. J. Tyrer, Br. J. Pharmacol., 45, 557 (1972). 147 P. Turner and A. Hedges, An investigation of the central effects of oxprenolol, in New perspectives in β-blockade, D. N. Burley, J. H. Frier, R. K. Rondel, and S. H. Taylor, Eds., Ciba, Horsham 1972, pp. 269– 272. 148 C. W. Ogle and P. Turner, J. Pharmacol. Clin., 1, 256– 261 (1974). 149 P. F. C. Bayliss and S. M. Duncan, Br. J. Clin. Pharmacol., 2, 527– 531 (1975). 150 S. Nakano, H. K. Gillespie, and L. E. Hollister, Psychopharmacology, 59, 279– 284 (1978). 151 G. E. Foster, C. Makin, D. F. Evans, and J. D. Hardcastle, Br. J. Surg., 67, 609– 612 (1980). Citing Literature Volume1, Issue4Winter 1981Pages 387-410 ReferencesRelatedInformation